US generics drugmaker Mylan (Nasdaq: MYL) has confirmed that it has been sued by German pharma major Bayer (BAYN: DE) and partner Onyx Pharmaceuticals (a subsidiary of Amgen [Nasdaq: AMGN]), in connection with the filing of an Abbreviated New Drug Application with the US Food and Drug Administration for sorafenib tablets, 200mg.
This product is the generic version of Bayer’s Nexavar, which is indicated for the treatment of certain types of cancers including unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze